AU2021260018A1 - Medical use of daridorexant - Google Patents

Medical use of daridorexant Download PDF

Info

Publication number
AU2021260018A1
AU2021260018A1 AU2021260018A AU2021260018A AU2021260018A1 AU 2021260018 A1 AU2021260018 A1 AU 2021260018A1 AU 2021260018 A AU2021260018 A AU 2021260018A AU 2021260018 A AU2021260018 A AU 2021260018A AU 2021260018 A1 AU2021260018 A1 AU 2021260018A1
Authority
AU
Australia
Prior art keywords
sleep
daridorexant
daytime
subject
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021260018A
Other languages
English (en)
Inventor
Guy Braunstein
Scott PAIN
Dalma SEBOEK-KINTER
Cedric VAILLANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AU2021260018A1 publication Critical patent/AU2021260018A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021260018A 2020-04-19 2021-04-16 Medical use of daridorexant Pending AU2021260018A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2020060940 2020-04-19
EPPCT/EP2020/060940 2020-04-19
PCT/EP2021/059943 WO2021213923A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Publications (1)

Publication Number Publication Date
AU2021260018A1 true AU2021260018A1 (en) 2022-12-22

Family

ID=75478068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021260018A Pending AU2021260018A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Country Status (14)

Country Link
US (1) US20230134935A1 (https=)
EP (1) EP4138822A1 (https=)
JP (1) JP7822954B2 (https=)
KR (1) KR20230004670A (https=)
CN (1) CN115427037A (https=)
AU (1) AU2021260018A1 (https=)
BR (1) BR112022020924A2 (https=)
CA (1) CA3175369A1 (https=)
CL (1) CL2022002855A1 (https=)
IL (1) IL297234A (https=)
MX (1) MX2022011179A (https=)
PH (1) PH12022552763A1 (https=)
TW (1) TW202200133A (https=)
WO (1) WO2021213923A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502447A (ja) * 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba

Also Published As

Publication number Publication date
CA3175369A1 (en) 2021-10-28
TW202200133A (zh) 2022-01-01
JP2023521492A (ja) 2023-05-24
BR112022020924A2 (pt) 2023-02-14
MX2022011179A (es) 2022-10-07
WO2021213923A1 (en) 2021-10-28
KR20230004670A (ko) 2023-01-06
JP7822954B2 (ja) 2026-03-03
IL297234A (en) 2022-12-01
US20230134935A1 (en) 2023-05-04
EP4138822A1 (en) 2023-03-01
CL2022002855A1 (es) 2023-06-02
CN115427037A (zh) 2022-12-02
PH12022552763A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
JP6332651B2 (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
CN113993522A (zh) 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US12485100B2 (en) Treatment of menstrual cycle-induced symptoms
MacDonald et al. Current therapies and drug development pipeline in lewy body dementia: an update
JP7822954B2 (ja) ダリドレキサントの医学的用途
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
EA051128B1 (ru) Медицинское применение даридорексанта
Khan et al. Diphenhydramine: a review of its clinical applications and potential adverse effect profile
Collins et al. Pediatric cancer pain
Brown et al. Psychiatric disorders
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
Neubauer Effective Ways to Manage Insomnia: Improving Outcomes through Optimal Treatment Strategies
Rutkofsky et al. Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review
HK40075517A (en) Treatment of menstrual cycle-induced symptoms
HK40075517B (en) Treatment of menstrual cycle-induced symptoms
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
Fleming 3.3 Sleep Difficulties and Disorders in Older Adults, and Their Management
REINEMER APPROVED BY THE GRADUATE COUNCIL, COLLEGE^ PF—DENTISTRY:(signed) _ f Assistant Dean of Research and Advanced Education APPROVED BY THE GRADUATE COUNCIL
HK40032890A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Aronoff et al. Adjuvant Analgesics in Neuropathic Pain
Ramos et al. Nonfatal suicidal olanzapine intoxication: a case report
HK1084894A1 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight